Please login to the form below

Not currently logged in
Email:
Password:

Epclusa

This page shows the latest Epclusa news and features for those working in and with pharma, biotech and healthcare.

Merck & Co pulls out of hepatitis C R&D as market shrinks

Merck & Co pulls out of hepatitis C R&D as market shrinks

In the same period, Gilead’s HCV portfolio of Harvoni (sofosbuvir/ledipasvir), Epclusa (sofosbuvir/velpatasvir) and Sovaldi (sofosbuvir) brought in $5.44bn, down from around $8.3bn in the first half

Latest news

  • Gilead gets OK for three-in-one hep C therapy in US Gilead gets OK for three-in-one hep C therapy in US

    The single-tablet triple therapy contains NS5B polymerase inhibitor sofosbuvir and NS5A inhibitor velpatasvir - the two active ingredients in Gilead's recently-approved two-drug HCV combination Epclusa - as well as ... Sovaldi and follow-ups Harvoni and

  • Two new hepatitis C therapies fast-tracked in Europe Two new hepatitis C therapies fast-tracked in Europe

    It is dosed once daily as three oral tablets and is being billed as a rival to Epclusa, which is dosed over 12 weeks in all patients. ... Analysts at Leerink have previously predicted that combined sales of Harvoni, Sovaldi and Epclusa will be $2.5bn a

  • Gilead files hepatitis C salvage regimen in US Gilead files hepatitis C salvage regimen in US

    Gilead files hepatitis C salvage regimen in US. Seeks FDA approval for combination of Epclusa and voxilaprevir. ... The SVR rates were comparable between the new regimen and Epclusa in both trials.

  • SMC approves Opdivo combo as first-line skin cancer treatment SMC approves Opdivo combo as first-line skin cancer treatment

    SMC approves Opdivo combo as first-line skin cancer treatment. Also backs Gilead’ s Epclusa, Baxalta’ s Oncaspar, AZ’ s Lynparza and Amicus’ Galafold. ... Meanwhile, Gilead Sciences' chronic hepatitis C virus infection therapy Epclusa

  • Torrid times at Gilead lead to calls for a major M&A deal Torrid times at Gilead lead to calls for a major M&A deal

    HIV portfolio sales down almost 10% to $7.5bn despite strong $533m start for Epclusa. ... start for latest entrant Epclusa (sofosbuvir and velpatasvir), which contributed $533m in the quarter.

More from news
Approximately 8 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics